Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
- Submitting institution
-
The University of Manchester
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 64812473
- Type
- D - Journal article
- DOI
-
10.1056/NEJMoa1708984
- Title of journal
- New England Journal Of Medicine
- Article number
- -
- First page
- 331
- Volume
- 378
- Issue
- -
- ISSN
- 1533-4406
- Open access status
- Not compliant
- Month of publication
- January
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
28
- Research group(s)
-
A - Cancer Sciences
- Citation count
- 262
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- I was involved in data acquisition, analysis and interpretation and critically reviewing the output for important intellectual content.
- Non-English
- No
- English abstract
- -
